On March 21, 2017 the Patent Trial and Appeal Board (PTAB) ruled in favor of Finnegan client Biogen, upholding a patent covering the multiple sclerosis drug Tecfidera in an inter partes review requested by the Coalition for Affordable Drugs. This was the Coalition's second failed attempt to invalidate the patent-in-suit. According to the decision, Biogen's experts presented sufficient evidence to demonstrate that a combination of previous patents, a clinical trial, and other prior art would not have made it obvious for an artisan to choose the 480 milligrams per day dosage cited in the patent.